New Hope For Women With Unexplained Infertility
Colchester, VT – September 30, 2015 – A new study carried out by the National Institutes of Health indicates that clomiphene citrate, a drug used to help aid fertility, is the most appropriate means to stimulate ovulation in unexplained infertility treated with intrauterine insemination.
This latest research shows that, of the 900 women treated with 4 cycles of clomiphene, conception occurred for 28%, with only 9% being multiple pregnancies (all twins).
Dr. Peter Casson, a founding partner of Northeastern Reproductive Medicine in Colchester Vermont and one of the principal Investigators for the National Institutes of Health funded Reproductive Medicine Network, states that:
“This trial demonstrates conclusively that, in terms of effectiveness and risk of multiple pregnancies, clomiphene in conjunction with intrauterine insemination remains far and away the most effective treatment for couples with unexplained infertility. This is important information for everyone suffering from this devastating condition, and I would like to thank all the local couples who participated in this trial for their contribution to this important study.“
Casson is an author of this and one other recent Reproductive Medicine Network study published in the New England Journal of Medicine; one of the most prestigious medical journals in the world. The first entitled “Letrozole Versus Clomiphene for Infertility in Polycystic Ovary Syndrome” is now widely recognized as a landmark study in the treatment of PCOS.
Unexplained infertility is said to occur when a couple cannot conceive, even though the female ovulates normally, has no obvious abnormalities in the reproductive tract, and the male is producing an adequate number of motile sperm. The most common treatment involves using drugs to stimulate the woman’s ovaries to release an egg, and inserting her partner’s sperm directly into the uterus (intrauterine insemination).
The assessment of Multiple Intrauterine Gestations from Ovarian Stimulation clinical trial was conducted at 12 locations throughout the United States. 900 women, between 18 and 40 years of age, took part in the research.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
About Northeastern Reproductive Medicine: Northeastern Reproductive Medicine consists of three Board-Certified Reproductive Endocrinologists and Infertility (REI) Physicians with extensive experience in the medical and surgical treatment of infertility and reproductive disorders. For more information about Northeastern Reproductive Medicine, visit our About Us page.
Dr. Peter Casson
105 West View Road Suite 302
Colchester, Vermont 05446